Educational Disclaimer: This article is for informational and educational purposes only. It does not constitute medical or legal advice. Regulatory requirements can change, and application of compounding law depends on the specific facts, product category, and jurisdiction.
503A vs 503B Compounding Pharmacies Explained
If you follow peptide, GLP-1, hormone, or sterile-injectable discussions, you have probably seen the terms 503A and 503B used as if everyone already knows the difference. In practice, they describe two different legal pathways for human drug compounding in the United States, with different rules around prescriptions, manufacturing standards, oversight, and distribution.
The short version is this:
- 503A refers to traditional pharmacy compounding for an identified individual patient, generally under state pharmacy oversight.[1][3]
- 503B refers to outsourcing facilities created by the Drug Quality and Security Act in 2013, which can compound sterile drugs without patient-specific prescriptions if they register with FDA and meet tighter federal requirements, including current good manufacturing practice (cGMP).[2][3][4]
That distinction matters because people often assume all compounders operate under the same rules. They do not. A 503A pharmacy and a 503B outsourcing facility may both produce compounded drugs, but the compliance framework around each one is materially different.
Key Takeaways
- 503A and 503B are not interchangeable labels. They refer to different sections of the Federal Food, Drug, and Cosmetic Act.[1][2]
- 503A compounding is tied to patient-specific prescriptions, with only limited anticipatory compounding allowed before the prescription arrives.[1]
- 503B outsourcing facilities may compound without prescriptions for identified individual patients, which is why they are commonly used for office stock or health-system supply.[2][4]
- 503B facilities are subject to cGMP and FDA risk-based inspection, while 503A pharmacies that qualify under section 503A are not subject to cGMP in the same way.[3][4]
- Neither 503A nor 503B compounded drugs are FDA-approved, and FDA states that approved drugs should be used when they can meet the patient need.[3][4]
Why These Categories Exist
Compounding has long existed to fill clinical gaps that approved, commercially manufactured drugs do not address. FDA gives examples such as removing a dye for a patient with an allergy or changing a dosage form when a tablet is not medically appropriate.
But Congress drew a line between:
- traditional, prescription-based compounding, and
- larger-scale sterile compounding for health systems and office use.
That line is reflected in two statutory sections:
- 21 U.S.C. § 353a for traditional pharmacy compounding, commonly called 503A.[1]
- 21 U.S.C. § 353b for registered outsourcing facilities, commonly called 503B.[2]
FDA says outsourcing facilities were established in 2013 by the Drug Quality and Security Act. In other words, 503B was designed as a distinct category, not just a bigger version of 503A.
What a 503A Compounding Pharmacy Is
Under section 503A, certain compounded drug products can qualify for exemptions from the FDA approval requirement, labeling with adequate directions for use, and cGMP requirements if the statutory conditions are met.
The central condition is the one most people should remember:
A 503A compounded drug is generally compounded for an identified individual patient based on receipt of a valid prescription order, or in limited quantities in advance based on a documented history of receiving such prescriptions within an established relationship.[1]
In practical terms, 503A usually means:
- the compounding is patient specific,
- the facility is a state-licensed pharmacy or federal facility, or a licensed physician compounding under the statute,[1]
- oversight is primarily state board of pharmacy day to day, with FDA still able to inspect and enforce federal law in appropriate situations,[3]
- and the pharmacy cannot simply behave like a conventional manufacturer while claiming 503A status.
Section 503A also limits what can be compounded from bulk drug substances, restricts compounding of products that are essentially copies of commercially available drugs, and places guardrails on interstate distribution.
What 503A does not mean
A 503A pharmacy is not an FDA-approved manufacturer, and the compounded products it dispenses are not FDA-approved drugs. It also does not mean the pharmacy can broadly produce office stock the way a registered outsourcing facility can.
What a 503B Outsourcing Facility Is
Section 503B created a separate federal pathway for facilities that elect to register with FDA as outsourcing facilities.
FDA describes an outsourcing facility as a facility that:
- is engaged in compounding sterile drugs and may also compound non-sterile drugs,
- has elected to register as an outsourcing facility,
- compounds by or under the direct supervision of a licensed pharmacist,
- is not required to be a licensed pharmacy, and
- may or may not obtain prescriptions for identified individual patients.
That last point is the major operational distinction. A 503B facility can compound without patient-specific prescriptions, which is why hospitals, clinics, surgery centers, and physician offices often look to 503B facilities for compounded sterile supply.
In practical terms, 503B usually means:
- office-use or health-system supply is possible without waiting for an individual prescription,
- the facility registers with FDA and pays annual establishment fees to remain registered,[4]
- the facility appears on FDA’s public list of registered outsourcing facilities if its registration is active,[5]
- and the facility is subject to FDA risk-based inspection and cGMP requirements.[3][4]
What 503B does not mean
It still does not mean the compounded drug is FDA-approved. Registration as an outsourcing facility also does not itself mean FDA has certified the facility as compliant at all times. FDA says registration means it received the required information, not that the facility is automatically in compliance with cGMP or all other 503B conditions.
The Simplest Way to Think About It
A useful shorthand is:
- 503A = prescription-first compounding
- 503B = outsourcing-facility compounding for broader clinical supply
That shorthand is not perfect, but it captures the operational difference most clearly.
If a drug is being compounded for a named patient pursuant to a valid prescription, you are usually in 503A territory.
If a facility is producing compounded sterile product without needing an identified individual patient prescription for each unit, and is doing so through FDA registration and cGMP compliance, you are in 503B territory.
Side-by-Side: 503A vs 503B
[See comparison table in original article]
Why cGMP Is Such a Big Part of the Conversation
One reason 503A and 503B get discussed so differently is the manufacturing standard.
FDA states plainly that drugs compounded in outsourcing facilities are subject to cGMP requirements, while drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with section 503A, are not.
That does not mean 503A pharmacies operate without standards. It means the statutory and regulatory framework is different. 503B facilities are closer to manufacturing-style federal quality oversight, especially for sterile production. That is one reason buyers often treat 503B status as relevant when evaluating compounded sterile supply for institutional use.
Just as important, FDA also warns that compounded drugs are not FDA-approved, regardless of whether they come from a 503A pharmacy or a 503B outsourcing facility. The distinction is about the legal and quality framework, not about FDA premarket approval.
Can a 503A Pharmacy Compound for Office Use?
This is one of the most common points of confusion.
At the federal level, section 503A is built around identified individual patients and valid prescriptions, with only limited anticipatory compounding tied to prescription history. That is very different from the 503B model, which expressly allows compounding without patient-specific prescriptions.
So when people say a clinic wants “office stock” or “buy-and-bill” style compounded supply, they are usually talking about the kind of demand that pushed Congress to create the 503B outsourcing facility category in the first place.
The exact answer in any real-world scenario can also depend on state law, the type of product, and FDA guidance. But as a federal framework question, 503A is the patient-specific pathway and 503B is the outsourcing-facility pathway.
Who Regulates Each Type of Facility?
FDA’s Q&A lays out the split clearly:
- State boards of pharmacy generally have primary day-to-day responsibility for state-licensed pharmacies that are not registered as outsourcing facilities.
- FDA primarily oversees facilities that register as 503B outsourcing facilities and inspects them on a risk-based schedule.
That means the compliance posture, inspection history, and publicly visible enforcement footprint may look different between the two categories.
For 503B facilities specifically, FDA says it generally updates the registered outsourcing facilities list on its website, and facilities must re-register annually if they want to remain registered.
Why Buyers, Clinics, and Researchers Care About the Distinction
The 503A versus 503B distinction matters because it changes what assumptions you can and cannot make.
If you are evaluating a 503A pharmacy
The key questions are usually:
- Is the compounding tied to a valid prescription for an identified individual patient?
- Is the pharmacy operating within the conditions required by section 503A?
- What state licensing and disciplinary history exists?
If you are evaluating a 503B outsourcing facility
The key questions are usually:
- Is the facility currently on FDA’s registered outsourcing facilities list?[5]
- Has it undergone FDA inspection, and what did FDA report?[4][5]
- Is the product being supplied in a context where non-patient-specific sterile compounding is the relevant pathway?
In other words, the label is not just semantics. It affects prescription workflow, procurement, compliance expectations, and the level of federal manufacturing oversight that applies.
What 503A and 503B Have in Common
Despite the differences, there are several important similarities.
1. Neither pathway creates FDA-approved drugs
FDA is explicit that compounded drugs are not FDA-approved.
2. Both pathways have statutory conditions
A facility does not get the exemptions simply by calling itself 503A or 503B. It has to satisfy the applicable legal conditions.
3. Both exist because approved drugs do not fit every real-world clinical scenario
Compounding still exists to address circumstances where an approved drug does not meet a specific need, even though FDA emphasizes that approved drugs should be used when they can adequately meet that need.
4. Both remain under FDA enforcement authority
Even though state boards play a major role with traditional compounding, FDA still has authority over insanitary conditions, misbranding, adulteration, and violations of the FD&C Act.
Common Misunderstandings
“503B is just a better 503A.”
Not exactly. It is a different legal category with different tradeoffs. 503B offers broader non-patient-specific compounding capability, but it also carries tighter federal obligations such as cGMP, registration, inspection, and adverse-event reporting.
“503A drugs are FDA-approved if they are prescribed.”
No. Patient-specific prescription compounding under 503A does not make the product FDA-approved.
“If a facility is registered as a 503B, FDA has endorsed every product it makes.”
Also no. FDA says registration means it has received the required information, not that the facility is automatically compliant at all times or that its compounded drugs are approved.
“503A and 503B are only relevant for pharmacies.”
Not really. The distinction matters to clinics, physician practices, hospitals, surgery centers, telehealth operators, and procurement teams because it affects how compounded drugs can legally be supplied and under what oversight framework.
Bottom Line
503A and 503B describe two different compounding pathways under U.S. federal law.
- 503A is the traditional, patient-specific compounding model built around valid prescriptions for identified individual patients.[1]
- 503B is the outsourcing-facility model created for registered facilities that can compound sterile drugs without patient-specific prescriptions, subject to cGMP and FDA risk-based inspection.[2][3][4]
If you remember only one thing, remember this:
503A is centered on the prescription. 503B is centered on the facility.
That single distinction explains most of the operational, compliance, and procurement differences people care about.
Common Questions
Are 503A and 503B compounded drugs FDA-approved?
No. FDA states that compounded drugs are not FDA-approved, which means FDA does not review them through the same premarket approval process used for approved drugs.
Can a 503B outsourcing facility compound without patient-specific prescriptions?
Yes. FDA says outsourcing facilities may or may not obtain prescriptions for identified individual patients.
Are 503A pharmacies subject to cGMP?
Not in the same way as 503B outsourcing facilities when they qualify under section 503A. FDA states that drugs compounded in outsourcing facilities are subject to cGMP, while drugs compounded under section 503A are not.
Who regulates a 503A pharmacy versus a 503B outsourcing facility?
FDA says state boards of pharmacy generally have primary day-to-day responsibility for state-licensed pharmacies that are not registered as outsourcing facilities, while 503B outsourcing facilities are primarily overseen by FDA and inspected on a risk-based schedule.
How can you check whether a 503B facility is currently registered?
FDA maintains a public list of registered outsourcing facilities and updates it as registrations change.
References
- 21 U.S.C. § 353a, “Pharmacy compounding.” Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/353a
- 21 U.S.C. § 353b, “Outsourcing facilities.” Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/353b
- U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- U.S. Food and Drug Administration. “Questions and Answers: Outsourcing Facility Registration.” https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
- U.S. Food and Drug Administration. “Registered Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
